

Sandoz, A Novartis Division



Sustainability of Antibiotics – Public Meeting, Presidential Advisory Council on Combating Antibiotic-resistant Bacteria

Harshika Sarbajna

Global Head, Anti-infectives, Sandoz International GmbH

January 2019

**Most bacterial infections are still treatable
with existing antibiotics...**




Lets keep it that way!

#keep-antibiotics-working

One cause of AMR we don't talk enough about – poor access to right antibiotics!



Lack of timely access to the right antibiotics



Suboptimal treatments; delayed action




- **Increased costs**
- **Higher chances of mortality and morbidity**
 - **Exacerbates the problem of AMR!**

Reasons behind poor access go beyond customer affordability in developed markets



ECONOMIC

Issues with market attractiveness – pricing mechanisms, tender practices, cost containment measures



SUPPLY CHAIN

Fragile supply chain with too few API or other suppliers, surge in demand or limited capacities



REGULATORY


Regulatory time lag and often differing national requirements across countries



QUALITY


Unanticipated issues related to quality

Fix for the long term - Need more carrots than sticks



- **Hold industry accountable** *for quality & reliability - not the lowest price*
- **Promote a healthy market** – *price by value instead of lowest cost*
- **Publish essential Antibiotics list**
- **Simplify marketing authorization/revision process**
- **Streamline supply alternatives, including alternative therapies or international products**

Collaboration is key!



Thank You!